Xbrane Biopharma Q4 2023: Navigating muddy waters

Research Update

2024-03-01

07:55

Redeye comments on Xbrane’s year-end report, updates its forecasts following recent developments, and adjusts its valuation for the rights issue which has had large implications on the share price.

FE

Filip Einarsson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.